D
Dirk B. Mendel
Researcher at University of California, Davis
Publications - 18
Citations - 4168
Dirk B. Mendel is an academic researcher from University of California, Davis. The author has contributed to research in topics: Receptor tyrosine kinase & Platelet-derived growth factor receptor. The author has an hindex of 14, co-authored 18 publications receiving 4072 citations.
Papers
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal Article
A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo
James G. Christensen,Randall E. Schreck,Jon Burrows,Poonam Kuruganti,Emily Chan,Phuong Le,Jeffrey H. Chen,Xueyan Wang,Lany Ruslim,Robert A. Blake,Kenneth E. Lipson,John Ramphal,Steven Do,Jingrong Jean Cui,Julie M. Cherrington,Dirk B. Mendel +15 more
TL;DR: The feasibility of selectively targeting c-Met with ATP-competitive small-molecules with high selectivity is demonstrated and the therapeutic potential of targetingc-Met in human cancers is suggested.
Journal Article
SU11248 Maintenance Therapy Prevents Tumor Regrowth after Fractionated Irradiation of Murine Tumor Models
Aaron J. Schueneman,Eric Himmelfarb,Ling Geng,Jiahua Tan,Edwin F. Donnelly,Dirk B. Mendel,Gerald McMahon,Dennis E. Hallahan +7 more
TL;DR: SU11248 enhances radiation-induced endothelial cytotoxicity, resulting in tumor vascular destruction and tumor control when combined with fractionated radiotherapy in murine tumor models, and inhibition of angiogenesis well beyond radiation therapy may be a promising treatment paradigm for refractory human neoplasms.
Journal Article
Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies,
Cheryl A. London,Alison L. Hannah,Regina Zadovoskaya,May B. Chien,Cynthia Kollias-Baker,Mona P. Rosenberg,Sue Downing,G. S. Post,Joseph F. Boucher,Narmada Shenoy,Dirk B. Mendel,Gerald McMahon,Julie M. Cherrington +12 more
TL;DR: This study provides the first evidence that p.o. administered kinase inhibitors can exhibit activity against a variety of spontaneous malignancies in dogs, and it is likely that such agents will demonstrate comparable antineoplastic activity in people.
Journal Article
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Dirk B. Mendel,Randall E. Schreck,David C. West,Guangmin Li,Laurie M. Strawn,Sheila S. Tanciongco,Stefan Vasile,Laura K. Shawver,Julie M. Cherrington +8 more
TL;DR: The durability of the in vitro activity of SU5416 was shown to be attributable to its long-lasting ability to specifically inhibit VEGF-dependent phosphorylation of Flk-1/KDR and subsequent downstream signaling, althoughSU5416 is not an irreversible inhibitor of FlKDR tyrosine kinase activity.